Matt Ottmer

Matt Ottmer has extensive work experience in the biotechnology and pharmaceutical industries. Matt is currently the Chief Executive Officer at Kisbee Therapeutics, where they lead the development of therapeutic agents for neurodegenerative diseases. Prior to this role, they served as a Government Affairs Committee Member at the American Society of Gene & Cell Therapy from 2019 to 2021. Matt also worked as an Independent Consultant, serving as a Strategic Advisor before joining Kisbee Therapeutics.

Earlier in their career, Matt held various leadership positions at Voyager Therapeutics, Momenta Pharmaceuticals, Biogen, and Medtronic. At Voyager Therapeutics, they served as the Chief Operating Officer and Head of Corporate Strategy from 2017 to 2020. Matt was the Chief Operating Officer at Momenta Pharmaceuticals from 2015 to 2017. During their time at Biogen, Matt held several roles, including Senior Vice President of Strategy & Emerging Businesses, Head of Tysabri Franchise, and Chief of Staff to the CEO.

Prior to their roles in the biotechnology and pharmaceutical industries, Matt gained experience as a Market Development Intern at Medtronic and an Associate Business Analyst at A.T. Kearney. Overall, Matt Ottmer's work experience reflects their expertise in leadership, strategy, and operations within the healthcare sector.

Matt Ottmer attended the University of Michigan from 1989 to 1993, where they obtained a Bachelor of Arts degree. During their time there, they focused their studies on Political Science and Pre-Med. Later on, from 1997 to 1999, Matt pursued a Master of Business Administration (MBA) degree at Northwestern University - Kellogg School of Management. Matt'scoursework covered various subjects, including Finance, Marketing, and Health Care.